Cargando…

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

AIMS: Oligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen receptor-targeted therapy (ARTT)]. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Priyanka H., Tunariu, Nina, Levine, Daniel S., de Bono, Johann S., Eeles, Rosalind A., Khoo, Vincent, Murray, Julia, Parker, Christopher C., Pathmanathan, Angela, Reid, Alison, van As, Nicholas, Tree, Alison C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152030/ https://www.ncbi.nlm.nih.gov/pubmed/35656509 http://dx.doi.org/10.3389/fonc.2022.862995

Ejemplares similares

A case of repeat oligoprogressive castration‐resistant prostate cancer treated with pulmonary metastasectomy
por: Soma, Takahiko, et al.
Publicado: (2023)

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
por: Bianchini, Diletta, et al.
Publicado: (2017)

The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
por: Patel, P.H., et al.
Publicado: (2019)

Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response
por: Parker, Chris, et al.
Publicado: (2023)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer Recurrence Revealed by Choline PET/CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer
por: Nguyen, Thu-Cuc, et al.
Publicado: (2018)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223
por: Hijab, Adham, et al.
Publicado: (2021)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
por: Attard, G, et al.
Publicado: (2006)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

Prostate cancer – Advantages and disadvantages of MR-guided RT
por: Murray, Julia, et al.
Publicado: (2019)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
por: Lorente, D, et al.
Publicado: (2014)

The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
por: Parker, Daniel C., et al.
Publicado: (2020)

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies
por: Le, Uyen-Thao, et al.
Publicado: (2023)

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer
por: Meisel, Alexander, et al.
Publicado: (2022)

Genomics of lethal prostate cancer at diagnosis and castration resistance
por: Mateo, Joaquin, et al.
Publicado: (2020)

Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI
por: Pathmanathan, Angela U., et al.
Publicado: (2019)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
por: Lozano, Rebeca, et al.
Publicado: (2021)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Oligoprogression in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

THU544 Prostatic Acid Phosphatase Is Negatively Regulated By Androgens And Persists In Castrate-resistant Metastatic Prostate Cancer
por: Rajagopalan, Vinodh, et al.
Publicado: (2023)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
por: Mateo, Joaquin, et al.
Publicado: (2020)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
por: Delanoy, Nicolas, et al.
Publicado: (2021)

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel
por: Armstrong, Andrew J., et al.
Publicado: (2017)

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin
por: Mak, Blossom, et al.
Publicado: (2022)

Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
por: Tree, Alison, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_btrqe7f4rspbkqdu4acdlq9len